Chu, H.H.; Kim, J.H.; Shim, J.H.; Yoon, S.M.; Kim, P.H.; Alrashidi, I.
Chemoembolization Plus Radiotherapy versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers 2020, 12, 1116.
https://doi.org/10.3390/cancers12051116
AMA Style
Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I.
Chemoembolization Plus Radiotherapy versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers. 2020; 12(5):1116.
https://doi.org/10.3390/cancers12051116
Chicago/Turabian Style
Chu, Hee Ho, Jin Hyoung Kim, Ju Hyun Shim, Sang Min Yoon, Pyeong Hwa Kim, and Ibrahim Alrashidi.
2020. "Chemoembolization Plus Radiotherapy versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis" Cancers 12, no. 5: 1116.
https://doi.org/10.3390/cancers12051116
APA Style
Chu, H. H., Kim, J. H., Shim, J. H., Yoon, S. M., Kim, P. H., & Alrashidi, I.
(2020). Chemoembolization Plus Radiotherapy versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers, 12(5), 1116.
https://doi.org/10.3390/cancers12051116